Literature DB >> 20167923

Diagnostic criteria and yield of real-time transcranial Doppler monitoring of intra-arterial reperfusion procedures.

Marta Rubiera1, Luis Cava, Georgios Tsivgoulis, Damon E Patterson, Limin Zhao, Yi Zhang, Aaron M Anderson, Alice Robinson, Mark R Harrigan, Edward Underwood, Joseph Horton, Andrei V Alexandrov.   

Abstract

BACKGROUND AND
PURPOSE: Intra-arterial (IA) rescue procedures are increasingly used to treat acute ischemic stroke. We implemented continuous transcranial Doppler (TCD) monitoring during these procedures to detect any potentially harmful flow changes. Here, we report diagnostic criteria and yield of TCD monitoring.
METHODS: We studied consecutive acute stroke patients who underwent IA reperfusion procedures. TCD flow signatures during these procedures were analyzed and any abnormal findings were documented.
RESULTS: Patients were included only if there was successful insonation through the skull; of 56 eligible patients, 51 were included. IA procedures included IA tissue plasminogen activator, use of the Merci retriever, the Penumbra system, balloon angioplasty, and stenting. On TCD monitoring, contrast injections produced high-intensity signals and increased the mean flow velocity (MFV). Deployment of the Merci device appeared as high-intensity, short-duration signals with a transient MFV decrease of 11.5%. The Penumbra system produced lower-intensity signals with a greater transient decrease in MFV during aspiration. IA tissue plasminogen activator significantly increased MFV by 7.5% over Merci and Penumbra flow velocity changes. Power motion Doppler-TCD detected reocclusion in 13 patients, artery-to-artery embolization in 2 patients, air embolism in 2 patients, and hyperperfusion in 6 patients. Overall, the yield of TCD monitoring was positive in 23 (49%) patients who received IA reperfusion procedures.
CONCLUSIONS: Our velocity, intensity, and flow signatures criteria for TCD monitoring of IA reperfusion procedures detect reocclusion, hyperperfusion, or thromboembolism and air embolism in nearly half of all procedures. This hemodynamic information can be particularly helpful when neurological assessment is limited or delayed.

Entities:  

Mesh:

Year:  2010        PMID: 20167923     DOI: 10.1161/STROKEAHA.109.565762

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  5 in total

Review 1.  Vascular imaging in stroke: comparative analysis.

Authors:  Kristian Barlinn; Andrei V Alexandrov
Journal:  Neurotherapeutics       Date:  2011-07       Impact factor: 7.620

2.  Bringing forward reperfusion with oxygenated blood perfusion beyond arterial occlusion during endovascular procedures in patients with acute ischemic stroke.

Authors:  M Ribo; M Rubiera; J Pagola; D Rodriguez-Luna; P Meler; A Flores; J Alvarez-Sabin; C A Molina
Journal:  AJNR Am J Neuroradiol       Date:  2010-08-26       Impact factor: 3.825

3.  European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage.

Authors:  Else Charlotte Sandset; Craig S Anderson; Philip M Bath; Hanne Christensen; Urs Fischer; Dariusz Gąsecki; Avtar Lal; Lisa S Manning; Simona Sacco; Thorsten Steiner; Georgios Tsivgoulis
Journal:  Eur Stroke J       Date:  2021-05-11

4.  Association Between Post-procedure Cerebral Blood Flow Velocity and Severity of Brain Edema in Acute Ischemic Stroke With Early Endovascular Therapy.

Authors:  Jie Pan; Huadong Wu; Tingting Wu; Yu Geng; Ruozhen Yuan
Journal:  Front Neurol       Date:  2022-07-18       Impact factor: 4.086

5.  Practice recommendations for neurovascular ultrasound investigations of acute stroke patients in the setting of the COVID-19 pandemic: an expert consensus from the European Society of Neurosonology and Cerebral Hemodynamics.

Authors:  C Baracchini; A Pieroni; M Kneihsl; E Azevedo; M Diomedi; L Pascazio; J Wojczal; C Lucas; E Bartels; N M Bornstein; L Csiba; J Valdueza; G Tsivgoulis; B Malojcic
Journal:  Eur J Neurol       Date:  2020-06-18       Impact factor: 6.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.